After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

CGT Global, a leading biotechnology company driving the development and delivery of innovative cell and gene therapies, today ...

Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

REGENXBIO Inc. announced it will initiate a pivotal phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy (DR) using suprachoroidal ...

Jonathan D. Grinstein, PhD, Manfred Scholz, PhD, and Erik Wiklund, PhD, go behind the headlines to address a shifting policy landscape and what it means for the future of chronic disease, diagnostics, ...

GAAP revenue of $14.2 million for Q2 2025 beat analyst estimates and Revenue more than doubled year over year in the second quarter, beating analyst estimates. Net loss per share (GAAP) narrowed to ...

Cancer survival has doubled in the past half a century, but around 167,000 people still die of the disease in the UK every ...

Are we doomed to repeat the mistakes of our parents? “Therapist Zero” is the story of a father determined to avoid the ...

A 38-year-old man in Italy has regained his sight after undergoing a groundbreaking experimental gene therapy—the first of its kind in the world. The patient, diagnosed with Usher syndrome type 1b, a ...